ReviewFrontiers in pharmacology2026
Pharmacokinetic profiling of rituximab in glomerular diseases: key determinants and implications for personalized therapy.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab demonstrates significant efficacy in the treatment of glomerular diseases; however, considerable heterogeneity in clinical responses is observed. This variability is largely attributable to the complex pharmacokinetic profile of rituximab, which is a key determinant of interindividual differences in treatment outcomes. To systematically elucidate the pharmacokinetic characteristics of rituximab across different glomerulopathies and their association with clinical efficacy, this review synthesizes current literature, with a focus on analyzing the impact of key variables, including proteinuria, anti-drug antibodies, and competition for the neonatal Fc receptor, on drug clearance. Furthermore, we compare the dynamic serum concentration profiles and therapeutic outcomes of rituximab in membranous nephropathy, minimal change disease, and lupus nephritis. The findings reveal that the pharmacokinetics of rituximab in patients with glomerular diseases are highly heterogeneous, modulated by both disease-specific factors (for example, damage to the glomerular filtration barrier leads to the urinary loss of proteins) and patient-intrinsic factors (such as polymorphisms in the Neonatal Fc Receptor gene). Available evidence indicates that subtherapeutic drug exposure is closely associated with incomplete B-cell depletion and suboptimal clinical remission. Based on these insights, we identify critical monitoring timepoints for early detection of insufficient exposure (for instance, months 2-3 in membranous nephropathy and month 2 in lupus nephritis). Nevertheless, current data are predominantly derived from retrospective and small-sample studies, and evidence-based target concentration ranges specific to glomerular diseases remain undefined. This review aims to provide an evidence-based rationale and practical recommendations for personalized dosing strategies guided by therapeutic drug monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.